Teva sells off contraceptive device in $1.1bn deal
By 
Jamie Durrani2017-09-14T11:31:00
CooperSurgical to acquire Paragard as Teva seeks to offload assets
Teva has agreed to sell its Paragard contraceptive product to women’s healthcare specialist CooperSurgical for $1.1 billion (£830 million) in cash. The deal includes Teva’s manufacturing site in Buffalo, US, where the intrauterine device is made.